We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Cancer Immunology – Products

Cell Therapy
Whitepaper

Advances in Cell Therapy

This article examines recent advancements in cell therapy research, from promising lab findings poised for clinical translation to enhancements in development, testing, and manufacturing processes.
Improving Cancer Patient Care With Professor Mark Lawler
Whitepaper

Improving Cancer Patient Care With Professor Mark Lawler

In this article, Mark Lawler, professor of digital health, answers your questions about these revolutionary techniques and discusses the barriers to their implementation in the clinic. Prof. Lawler has an international reputation in cancer research and a focus on developing a molecular understanding of cancer to improve patient care, including through precision medicine.
mRNA.
Product News

Lonza and Oxford Nanopore To Collaborate on Novel Test To Accelerate Analysis of mRNA Products

Collaboration aims to commercialize a Current Good Manufacturing Practice (cGMP) validated test to enable advanced and innovative analysis for multiple critical quality attributes of mRNA products.
Novel CAR Technology To Transform Cancer Therapy
Whitepaper

Novel CAR Technology To Transform Cancer Therapy

Chimeric antigen receptor (CAR) therapies involve the use of engineered receptors capable of redirecting immune cells to recognize and destroy cancer cells expressing a specific antigen. Currently, CAR T cells dominate the field of CAR therapy.
GMP & RUO Grade iPSC Gene Editing & Differentiation Services
Product
Advertisement

GMP & RUO Grade iPSC Gene Editing & Differentiation Services

Complete iPSC/MSC manufacturing platform: Generate, CRISPR engineer, and differentiate iPSCs into NK cells, T cells, neurons, or cardiomyocytes at Applied StemCell’s new GMP manufacturing facility in Milpitas, California.
Cancer cells.
Product News

Xsphera Biosciences and NEX-I Collaborate To Advance Oncology Drug Research

Xsphera Biosciences, is pleased to announce the formalization of a Memorandum of Understanding (MOU) with NEX-I, a Seoul-based pioneer in immune-oncology therapeutics.
Product
Advertisement

CAR-T Target Luciferase Reporter Cells

CAR-T Target Luciferase Reporter Cells that have high endogenous expression of CD19, CD20, and HER2, which makes them more physiologically relevant as in vitro tools to develop adoptive CAR-T cell therapies.
A doctor holding a clipboard with a patient.
Product News

OncoHost To Present Proteomics-Based Predictive Biomarker for Immune-Related Adverse Events in NSCLC Patients

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.
Cells.
Product News

Laverock Therapeutics Secures Innovate UK Award To Advance Immune Effector Cell Therapeutics Programme

Laverock Therapeutics secures £1m funding via the Innovate UK Investor Partnerships Future Economy programme, supported by UKI2S.
Unlocking the Potential of Cancer Immunotherapy with 3D Immune Cell Killing Assays
Whitepaper

Unlocking the Potential of Cancer Immunotherapy with 3D Immune Cell Killing Assays

This literature review explores the latest in 3D immune cell killing assays for cancer immunotherapy research.
Advertisement